CRDF
Price
$2.06
Change
+$0.10 (+5.10%)
Updated
Sep 4, 01:58 PM (EDT)
Capitalization
130.72M
56 days until earnings call
QURE
Price
$17.38
Change
+$0.37 (+2.18%)
Updated
Sep 3 closing price
Capitalization
954.68M
55 days until earnings call
Interact to see
Advertisement

CRDF vs QURE

Header iconCRDF vs QURE Comparison
Open Charts CRDF vs QUREBanner chart's image
Cardiff Oncology
Price$2.06
Change+$0.10 (+5.10%)
Volume$2.59K
Capitalization130.72M
uniQure
Price$17.38
Change+$0.37 (+2.18%)
Volume$1.48M
Capitalization954.68M
CRDF vs QURE Comparison Chart in %
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. QURE commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Hold and QURE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (CRDF: $1.96 vs. QURE: $17.38)
Brand notoriety: CRDF and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 55% vs. QURE: 138%
Market capitalization -- CRDF: $130.72M vs. QURE: $954.68M
CRDF [@Biotechnology] is valued at $130.72M. QURE’s [@Biotechnology] market capitalization is $954.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, QURE is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 5 TA indicator(s) are bullish while QURE’s TA Score has 6 bullish TA indicator(s).

  • CRDF’s TA Score: 5 bullish, 5 bearish.
  • QURE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, QURE is a better buy in the short-term than CRDF.

Price Growth

CRDF (@Biotechnology) experienced а -9.68% price change this week, while QURE (@Biotechnology) price change was +10.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.71%. For the same industry, the average monthly price growth was +5.90%, and the average quarterly price growth was +27.78%.

Reported Earning Dates

CRDF is expected to report earnings on Oct 30, 2025.

QURE is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (-0.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($955M) has a higher market cap than CRDF($131M). QURE YTD gains are higher at: -1.586 vs. CRDF (-54.839). CRDF has higher annual earnings (EBITDA): -53.95M vs. QURE (-119.56M). QURE has more cash in the bank: 377M vs. CRDF (71M). CRDF has less debt than QURE: CRDF (1.19M) vs QURE (66.7M). QURE has higher revenues than CRDF: QURE (14.3M) vs CRDF (545K).
CRDFQURECRDF / QURE
Capitalization131M955M14%
EBITDA-53.95M-119.56M45%
Gain YTD-54.839-1.5863,459%
P/E RatioN/AN/A-
Revenue545K14.3M4%
Total Cash71M377M19%
Total Debt1.19M66.7M2%
FUNDAMENTALS RATINGS
CRDF vs QURE: Fundamental Ratings
CRDF
QURE
OUTLOOK RATING
1..100
5226
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9337
P/E GROWTH RATING
1..100
10091
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (54) in the null industry is in the same range as QURE (78) in the Biotechnology industry. This means that CRDF’s stock grew similarly to QURE’s over the last 12 months.

CRDF's Profit vs Risk Rating (100) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to QURE’s over the last 12 months.

CRDF's SMR Rating (99) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that CRDF’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for CRDF (93) in the null industry. This means that QURE’s stock grew somewhat faster than CRDF’s over the last 12 months.

QURE's P/E Growth Rating (91) in the Biotechnology industry is in the same range as CRDF (100) in the null industry. This means that QURE’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDFQURE
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 23 days ago
87%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLWYF31.44N/A
N/A
Bellway Plc.
BORUF4.25N/A
N/A
Borussia Dortmund GMBH & Co.
JETMF0.67N/A
N/A
Global Crossing Airlines Group Inc.
QQREF0.06N/A
N/A
Quebec Rare Earth Elements Corp.
TNABF2.89-0.24
-7.67%
Tenaga Nasional Berhad

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with QURE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
+0.51%
QURE - CRDF
42%
Loosely correlated
+2.18%
NAMS - CRDF
41%
Loosely correlated
+1.02%
MRVI - CRDF
41%
Loosely correlated
-0.42%
NRIX - CRDF
38%
Loosely correlated
+3.84%
AKBLF - CRDF
37%
Loosely correlated
N/A
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NAMS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
+2.18%
NAMS - QURE
57%
Loosely correlated
+1.02%
BEAM - QURE
48%
Loosely correlated
+15.02%
MGX - QURE
45%
Loosely correlated
-1.65%
ABSI - QURE
44%
Loosely correlated
+1.71%
ACLX - QURE
43%
Loosely correlated
+2.11%
More